|
1) 日本高血圧学会高血圧治療ガイドライン作成委員会. 高血圧治療ガイドライン2004. 東京: 日本高血圧学会; 2004
|
|
|
|
|
2) Fujita T, Ando K, Nishimura H, et al. On behalf of the Cilnidipine versus Amlodipine Randomized Trial for Evaluation in Renal Disease (CARTER) Study Investigators: Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int. 2007; 72: 1543-9
|
|
|
|
|
3) Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345: 851-60
|
|
|
|
|
|
4) Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005; 365: 939-46
|
|
|
|
|
|
5) Krespi PG, Makris TK, Hatzizacharias AN, et al. Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension. Cardiovasc Drug Ther. 1998; 12: 463-7
|
|
|
|
|
|
6) Amann K, Rump LC, Simonaviciene A, et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol. 2000; 11: 1469-78
|
|
|
|
|
|
7) Zhou X, Ono H, Ono Y, et al. N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002; 20: 993-1000
|
|
|
|
|
|
8) Konda T, Enomoto A, Matsushita J, et al. The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. Nephron Physiol. 2005; 101: 1-13
|
|
|
|
|
|
9) Kojima S, Shida M, Yokoyama H. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. Hypertens Res. 2004; 27: 379-85
|
|
|
|
|
10) Katayama K, Nomura S, Ishikawa H, et al. Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria. Kidney Int. 2006; 70: 151-6
|
|
|
|
|
|
11) Nakamura T, Sugaya T, Kawagoe Y, et al. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci. 2007; 333: 321-6
|
|
|
|
|
|
12) Shima E, Katsube M, Kato T, et al. Calcium channel blockers suppress cytokine-induced activation of human neutrophils. Am J Hypertens. 2008; 21: 78-84
|
|
|
|
|
|
13) Bakris GL, Toto RD, McCullough PA, et al. GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension) Study Investigators. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008; 73: 1303-9
|
|
|
|
|